Skip to content
Loop Biz – Lifestyle
Author:
Actinogen Medical
Xanamem proof-of-concept trial demonstrating anti-depressant activity published in the British Journal of Psychiatry
July 20, 2026
Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program
May 28, 2026
Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update
April 1, 2026